AstraZeneca's COVID Vaccine On Hold: A Reminder Drug Development Is Never Straightforward
The company – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event.
You may also be interested in...
The Indian regulator says it is not considering emergency use authorization for COVID-19 vaccines before completion of clinical trials, a stand validated by AstraZeneca halting trials of its vaccine candidate due to an adverse event in UK. Meanwhile, India has signed up for Phase III trials of Russia’s vaccine candidate
The clinical pause for AZD1222 errs on the side of caution, but raises questions about the viral vector’s safety.
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.